DIA Biosimilars 2013

Bionovo

Bionovo struggles to gain funding

Monday, March 12, 2012 03:40 PM

Bionovo, a pharmaceutical company focused on women's health and cancer, said it needs to obtain substantial additional funding to achieve its objectives of internally developing drugs.

More... »

Cenduit: Now with Patient Reminders

Boyle joins Bionovo

Friday, January 6, 2012 09:21 AM

Bionovo, a pharmaceutical company focusing on women’s health and cancer, has named David Boyle senior vice president and chief financial officer.

More... »

CRF Health – eCOA Forum

Bionovo enrolls first patient in phase III Menerba trial

Tuesday, November 22, 2011 02:36 PM

Bionovo has reported that the first patient has now been randomized and will begin dosing in the phase III pivotal clinical trial evaluating the safety and efficacy of two doses of Menerba (MF101) among a cohort of postmenopausal women for the treatment of menopausal hot flashes.

More... »

Bionovo initiates enrollment for phase III Menerba trial

Thursday, October 27, 2011 11:34 AM

Bionovo has started enrollment for the phase III pivotal clinical trial evaluating the safety and efficacy of two doses of Menerba (MF101) among a cohort of postmenopausal women for the treatment of menopausal hot flashes.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs